Pharmacy Benefits Management Services Home

Aug 02, 2010 · First to publish the discovery of novel phosphodiesterase type 5 inhibitors with better . in vitro . potency and selectivity compared to sildenafil. Contributed to discovery of 2 clinical candidates (PDE5 inhibitor, DPP4 inhibitor). Cephalon-Responsible for initial conception and development of several programs. ................
................